Popular Articles

Sotomayor Calls Roe 'Settled Law,' Says Health Of Woman Must Be Considered
During the second day of her Senate Judiciary Committee confirmation hearings, Supreme Court nominee Sonia Sotomayor said she views the 1973 Roe v. Wade decision legalizing abortion in the U.S. as settled law reaffirmed by subsequent Supreme Court rulings, the Washington Post reports (Goldstein et al., Washington Post, 7/15). At Tuesday"s hearing, lawmakers pressed Sotomayor on her views regarding abortion rights and Supreme Court precedent, the New York Times reports. She told committee members that the contraception rights case that is the foundation for Roe was "the precedent of the court, so it is settled law." She also said the 1992 ruling in Casey v. Planned Parenthood "reaffirmed the core holding of Roe," adding, "That is the precedent of the court and settled law in terms of the holding of the court" (Savage, New York Times, 7/15). Sotomayor said that "there is a right of privacy" and that the Supreme Court "has found it in various places in the Constitution." She cited the Fourth Amendment protection against unreasonable search and seizure and the 14th Amendment guaranteeing equal protection of the law (AP/Yahoo! News, 7/14).Sen. Orrin Hatch (R-Utah) asked Sotomayor if she considered the 2007 ruling in Gonzales v. Carhart an example of settled law. In the case, the court voted 5-4 to uphold the Partial-Birth Abortion Ban Act of 2003. The ruling was the first time since Roe that the court upheld an abortion restriction that made no exception for the health of the woman, the Times reports. In her response, Sotomayor said that "[a]ll precedent of the Supreme Court I consider settled law, subject to the deference the doctrine of stare decisis would counsel," although she did not address the health exception component of the Gonzales case.Sen. Dianne Feinstein (D-Calif.) later pressed Sotomayor to elaborate on her views on Gonzales. Feinstein noted that at least seven Supreme Court rulings prior to the 2007 case stated that abortion laws "cannot put a woman"s health at risk." She added that Gonzales "essentially removed this basic constitutional right for women." Feinstein asked Sotomayor, "When there are multiple precedents and a question arises, are all the previous decisions discarded, or should the court re-examine all the cases on point?" Sotomayor replied that she does not consider Gonzales to be a precedent making it settled law that health exceptions for abortion laws are constitutionally unnecessary. She said, "That was, I don"t believe, a rejection of its prior precedents," which are "still precedents of the court." Sotomayor added that the "health and welfare of a woman must be -- must be a compelling consideration." Feinstein pressed Sotomayor to clarify that she meant that it is still settled that abortion restrictions must have health exceptions. Sotomayor said, "It has been a part of the court"s jurisprudence and a part of its precedents. Those precedents must be given deference in any situation that arises before the court" (New York Times, 7/15).Sen. Lindsey Graham (R-S.C.) asked Sotomayor if the Constitution prohibits Congress or state legislatures "from defining life or regulating the rights of the unborn or protecting the right of the unborn in the first trimester?" Sotomayor began to cite the 14th Amendment to answer the question. Graham interrupted, asking, "[I]s there÷ anything in the document written about abortion?" Sotomayor said the "word "abortion" is not used in the Constitution, but the Constitution does have a broad provision concerning a liberty provision under the due process" clause (Holman, "NewsHour with Jim Lehrer," PBS, 7/14).Graham also asked Sotomayor about her work with the Puerto Rican Legal Defense and Education Fund, which had submitted legal briefs in the past that supported public funding for abortion coverage for low-income women. Sotomayor served on the group"s board from 1980 to 1992. She said that she "wasn"t aware of what was said in those briefs." She noted that she had served on the board but was not a lawyer for the gro
drugs without prescription
Preventing Breast Cancer The Focus Of 2009-2010 Susan G. Komen For The Cure Promise Grants
One of the most important challenges in the cancer community today is whether people can, in fact, prevent their own cancers. Susan G. Komen for the Cure® is announcing millions of dollars in long-term grant funding to find out.
News of the day
Delayed Muscle Response Complicates Sprained Ankle Rehab, BYU-Michigan Study Finds
Whether on the trail, at the gym, or even on the front-porch steps, what happens inside your ankle in the milliseconds following a single misstep could sentence you to a lifetime of ankle trouble.
Health Insurance

IKARIA(R) To In-License BioLineRx's BL-1040

Ikaria Holdings, Inc. and BioLineRx Ltd. (TASE: BLRX) announced that Ikaria has entered into an agreement to obtain a worldwide exclusive license to BioLineRx"s BL-1040, a potential breakthrough treatment for preventing pathological cardiac remodeling following acute myocardial infarction (AMI). BL-1040, currently in a phase I/II clinical trial, is administered via the coronary artery during standard catheterization and flows into the damaged heart muscle, where it forms a protective "scaffold" that enhances the mechanical strength of the heart muscle during recovery and repair. BL-1040 is the first program to graduate from the BIJ (BioLine Innovations Jerusalem) incubator subsidized by the Israeli Office of the Chief Scientist. Under the terms of the agreement, BioLineRx will receive upfront and milestone payments. BioLineRx will also receive royalties on annual net sales. Ikaria will be responsible for completing clinical development and commercialization efforts. The deal is contingent upon receipt of the approval of the Israeli Office of the Chief Scientist. "The acquisition of the rights to BL-1040 reinforces our commitment to deliver novel treatments to critically ill patients around the world," commented Daniel Tasse, President and CEO of Ikaria. "Millions of patients suffer from MI each year, and BL-1040 represents the potential of an exciting solution to the problem of ventricular remodeling following AMI, for which the unmet need remains very high." "This agreement is consistent with our business model of developing early-stage programs through human Proof of Concept trials and ultimately partnering with a global therapeutics company that has the expertise and res to complete development and commercialization," said Morris C. Laster, M.D., CEO of BioLineRx. "Ikaria"s deep and singular focus on therapies for patients in acute care settings makes it an ideal party to further develop and bring BL-1040 to the global market." About BL-1040 BL-1040 was invented by Professor Smadar Cohen from Ben-Gurion University and Professor Jonathan Leor from Tel-Aviv University. BioLineRx in-licensed the technology in 2005 from Ben-Gurion University through B.G. Negev Technologies and Applications Ltd. BL-1040 is currently in a Phase I/II pilot study in Germany and Belgium to determine the safety and feasibility of BL-1040 to treat AMI. Final results are anticipated in Q4 2009. About Ikaria Holdings, Inc. Ikaria Holdings, Inc. is a biotherapeutics company whose acute care products and therapies address the significant unmet needs of critically ill patients. The company"s lead product, INOmax(R) (nitric oxide) for inhalation, is the only FDA-approved drug for the treatment of hypoxic respiratory failure in term and near-term newborns, and also is marketed in Canada, Europe, Latin America and Australia. INOmax is approved for marketing in Japan and Mexico. Ikaria is engaged in new and ongoing clinical development of INOmax, carbon monoxide for inhalation and hydrogen sulfide. Ikaria also acquired the North American rights to terlipressin, which currently is under review by the FDA for the treatment of hepatorenal syndrome Type 1. Ikaria is headquartered in Clinton, NJ, with research facilities in Seattle, WA and Madison, WI, and a manufacturing facility in Port Allen, LA. Ikaria Holdings, Inc


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):